Open Nav

Please submit your session questions in advance at

Regulatory Changes to Cross-Border Investments: CFIUS and Biotech Deals

New national security regulations under the Foreign Investment Risk Review Modernization Act (FIRRMA) are changing the landscape for cross-border investments in biotechnology. In November 2018, new rules for a “pilot program” apply to foreign investors into U.S. companies who now need to file with the Committee on Foreign Investment in the United States (CFIUS) to approve covered transactions before entering licensing deals or other equity investments. This session will update market participants on the evolving national security review process and its impact on the biotechnology industry, as well as consider how additional rules may impact future business development and investment opportunities.

Moderator: Lisa Schaefer, Director, Tax & Financial Services Policy, Biotechnology Innovation Organization (BIO)

  • Date:Tuesday, February 12
  • Time:1:00 PM - 1:55 PM
  • Room:Shubert Complex
  • Location:6th Floor
  • Session Type:Educational Panel
  • Please submit your session questions in advance:

    Click here.

Lisa Schaefer
Biotechnology Innovation Organization (BIO)
Jun Bao
Impact Therapeutics
Joseph Benkert
Morrison & Foerster LLP
Jeff Farrah
National Venture Capital Association (NVCA)
Kimberly Nearing
Cedrus Group